Search

Your search keyword '"Shields, Jerry A."' showing total 104 results
Start Over Author "Shields, Jerry A." Journal journal of pediatric ophthalmology & strabismus
104 results on '"Shields, Jerry A."'

1. Likelihood of Germline Mutation With Solitary Unilateral Retinoblastoma Based on Patient Age at Presentation: Analysis of 482 Consecutive Patients

Author

Shields, Carol L., primary, Dockery, Philip, additional, Ruben, Megan, additional, Yaghy, Antonio, additional, Sunday, Madalyne A., additional, Duffner, Emily R., additional, Levin, Hannah J., additional, Taylor, Olivia S., additional, Calotti, Martin, additional, Lally, Sara E., additional, and Shields, Jerry A., additional

Published
2021
Full Text
View/download PDF

21. Retinoblastoma

Author

Shields, Carol L. and Shields, Jerry A.

Published
2003

39. Indocyanine Green-Enhanced Transpupillary Thermotherapy for Retinoblastoma: nalysis of 42 Tumors.

Author

Hasanreisoglu, Murat, Saktanasate, Jarin, Schwendeman, Rachel, Shields, Jerry A., and Shields, Carol L.

Subjects
INDOCYANINE green, THERMOTHERAPY, RETINOBLASTOMA, PUPIL diseases, OCULAR tumors
Abstract

Purpose: To evaluate the efficacy of indocyanine green-enhanced transpupillary thermotherapy (ICG-TTT) for retinoblastoma that shows suboptimal response to conventional treatments. Methods: A single center, retrospective chart review. The technique involved ICG infusion (range: 0.3 to 0.5 mg/kg) 1 minute prior to applying TTT using the indirect ophthalmoscope technique with a spot size of 1.2 mm. Results: There were 42 retinoblastomas in 30 eyes of 21 patients treated with ICG-TTT. The reasons for ICG enhancement included suboptimal response to standard TTT (n = 31, 74%), recurrence after standard TTT (n = 3, 7%), or minimally pigmented fundus with poor standard TTT uptake (n = 8, 19%). The mean patient age at treatment was 12 months (median: 11.6 months, range: 3 to 31 months). The mean tumor base was 3.5 mm (median: 3 mm), mean tumor thickness was 2.5 mm (median; 2 mm), mean distance to the foveola was 2.6 mm (median: 3 mm), and mean distance to the optic disc was 2.2 mm (median: 0.75 mm). Treatment parameters included a spot size of 1.2 mm, mean power of 760 mW (median: 800 mW, range: 400 to 1,200 mW), and mean duration of 4 minutes (median: 4 minutes, range: 0.5 to 14 minutes). Following a median of 2 sessions (range: 1 to 5 sessions) of ICG-TTT, 33 (79%) tumors demonstrated complete regression. The mean tumor thickness postoperatively was 1.7 mm. Two (5%) tumors showed minimal regression after ICG-TTT. During a mean follow-up of 46 months (median: 33 months), tumor recurrence after ICG-TTT developed in 7 (17%) cases at a mean interval of 7 months. Local complications of ICG-TTT included focal paraxial cataract (n = 2, 7%), iris atrophy (n = 1, 3%), and transient retinal hemorrhage (n = 2, 7%). Systemic problems included ICG allergy (n = 1, 5%). Overall, tumor control and globe salvage was achieved in all 30 (100%) eyes. There were no metastatic events. Conclusions: ICG-TTT is an effective alternative for reti-noblastoma control, particularly for small tumors that show suboptimal response to standard TTT. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results